JP7606537B2 - 神経筋疾患の処置のためのピリダジノン化合物 - Google Patents

神経筋疾患の処置のためのピリダジノン化合物 Download PDF

Info

Publication number
JP7606537B2
JP7606537B2 JP2022568794A JP2022568794A JP7606537B2 JP 7606537 B2 JP7606537 B2 JP 7606537B2 JP 2022568794 A JP2022568794 A JP 2022568794A JP 2022568794 A JP2022568794 A JP 2022568794A JP 7606537 B2 JP7606537 B2 JP 7606537B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
halogen
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022568794A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021231565A5 (https=
JP2023526248A5 (https=
JP2023526248A (ja
Inventor
ケビン コック，
ケビン ハント，
スティーブン シュラクター，
アラン ラッセル，
Original Assignee
エッジワイズ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジワイズ セラピューティクス， インコーポレイテッド filed Critical エッジワイズ セラピューティクス， インコーポレイテッド
Publication of JP2023526248A publication Critical patent/JP2023526248A/ja
Publication of JPWO2021231565A5 publication Critical patent/JPWO2021231565A5/ja
Publication of JP2023526248A5 publication Critical patent/JP2023526248A5/ja
Priority to JP2024218934A priority Critical patent/JP7715911B2/ja
Application granted granted Critical
Publication of JP7606537B2 publication Critical patent/JP7606537B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022568794A 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物 Active JP7606537B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218934A JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024439P 2020-05-13 2020-05-13
US63/024,439 2020-05-13
PCT/US2021/031979 WO2021231565A1 (en) 2020-05-13 2021-05-12 Pyridazinone compounds for the treatment of neuromuscular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218934A Division JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Publications (4)

Publication Number Publication Date
JP2023526248A JP2023526248A (ja) 2023-06-21
JPWO2021231565A5 JPWO2021231565A5 (https=) 2024-05-22
JP2023526248A5 JP2023526248A5 (https=) 2024-05-22
JP7606537B2 true JP7606537B2 (ja) 2024-12-25

Family

ID=76284178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568794A Active JP7606537B2 (ja) 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物
JP2024218934A Active JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218934A Active JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Country Status (4)

Country Link
US (1) US20230159513A1 (https=)
EP (2) EP4473968A3 (https=)
JP (2) JP7606537B2 (https=)
WO (1) WO2021231565A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4433473A1 (en) * 2021-11-17 2024-09-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
KR20240156632A (ko) * 2022-04-15 2024-10-30 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 Kif18a 억제제 및 이의 용도
CN121194963A (zh) 2023-03-27 2025-12-23 艾知怀斯治疗学公司 喹啉酮酰胺类化合物及其用途
WO2024206345A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2025207665A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinolinone compounds and uses thereof
WO2025207622A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinolinone, benzoxazinone, and quinoline compounds and uses thereof
WO2025207679A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2025207677A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinazolinone compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120289698A1 (en) 2011-04-22 2012-11-15 Ashcraft Luke W Certain heterocycles, compositions thereof, and methods for their use
US20180280385A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376667A (en) * 1992-12-31 1994-12-27 Entropin, Inc. Derivatives of benzoylecgonine, ecgonine and their multiple pharmacological properties
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
DK3877376T3 (da) * 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CA3118908A1 (en) * 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) * 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4433473A1 (en) * 2021-11-17 2024-09-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120289698A1 (en) 2011-04-22 2012-11-15 Ashcraft Luke W Certain heterocycles, compositions thereof, and methods for their use
US20180280385A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION

Also Published As

Publication number Publication date
EP4473968A2 (en) 2024-12-11
JP7715911B2 (ja) 2025-07-30
JP2025032327A (ja) 2025-03-11
EP4149620B1 (en) 2024-10-23
EP4149620A1 (en) 2023-03-22
US20230159513A1 (en) 2023-05-25
EP4473968A3 (en) 2025-03-26
WO2021231565A1 (en) 2021-11-18
JP2023526248A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
JP7606537B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
JP7357135B2 (ja) ピリダジノン化合物およびその使用
JP7429750B2 (ja) ピリダジノン化合物およびその使用
US12240833B2 (en) Pyridazinone compounds and uses thereof
JP7758687B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
US20230293518A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
US20230338375A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
US20230321091A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
JP2024540485A (ja) ピリダジノン化合物およびその使用
EA050889B1 (ru) Соединения пиридазинонов и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7606537

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150